Position in SGP
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$55,650,267
-$9,125,043 QoQ
Shares Held
2,500,012
0.0% QoQ
Ownership
7.47%
of shares outstanding
% of Portfolio
9.07%
of 13F equity value
Holder Rank
#3
of 51 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in SGP Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Sands Capital Alternatives, LLC holds $126,924,003 across 8 Biotechnology names. SGP ranks #1 (43.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | SGP |
SpyGlass Pharma, Inc.
This page
|
2,500,012 | $55,650,267 | |
| 2 | IKT |
Inhibikase Therapeutics, Inc.
|
13,018,965 | $26,428,498 | |
| 3 | ODTX |
Odyssey Therapeutics, Inc.
|
875,000 | $16,371,250 | |
| 4 | ABOS |
Acumen Pharmaceuticals, Inc.
|
3,720,105 | $9,932,680 | |
| 5 | TARS |
Tarsus Pharmaceuticals, Inc.
|
85,000 | $5,349,900 | |
| 6 | TSHA |
Taysha Gene Therapies, Inc.
|
724,873 | $4,936,385 | |
| 7 | CADL |
Candel Therapeutics, Inc.
|
405,837 | $4,180,121 | |
| 8 | ACRV |
Acrivon Therapeutics, Inc.
|
2,289,271 | $4,074,902 |
All Filings in SGP
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $55,650,267 | 2,500,012 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $64,775,310 | 2,500,012 | Shares | Sole | 2026-05-08 | |
| No filing history on record for this holder in this stock. | ||||||